Published in Infect Immun on October 20, 2014
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague. Vaccine (2015) 0.76
Animal Models for Salmonellosis: Applications in Vaccine Research. Clin Vaccine Immunol (2016) 0.75
Yersinia pestis Caf1 Protein: Effect of Sequence Polymorphism on Intrinsic Disorder Propensity, Serological Cross-Reactivity and Cross-Protectivity of Isoforms. PLoS One (2016) 0.75
Transfected Babesia bovis Expressing a Tick GST as a Live Vector Vaccine. PLoS Negl Trop Dis (2016) 0.75
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A (2000) 96.90
Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev (1997) 14.63
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Signal transduction and regulatory mechanisms involved in control of the sigma(S) (RpoS) subunit of RNA polymerase. Microbiol Mol Biol Rev (2002) 5.60
A low-Ca2+ response operon encodes the V antigen of Yersinia pestis. Infect Immun (1986) 2.39
Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol (1984) 2.32
Identification of a Salmonella virulence gene required for formation of filamentous structures containing lysosomal membrane glycoproteins within epithelial cells. Mol Microbiol (1996) 2.32
Metabolic load and heterologous gene expression. Biotechnol Adv (1995) 2.05
Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science (1998) 1.97
An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull World Health Organ (1960) 1.86
Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun (1999) 1.66
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 1.63
Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol (2003) 1.56
A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains. Microb Pathog (1988) 1.54
Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci U S A (1996) 1.52
Expression of the envelope antigen F1 of Yersinia pestis is mediated by the product of caf1M gene having homology with the chaperone protein PapD of Escherichia coli. FEBS Lett (1991) 1.48
The E. coli alpha-hemolysin secretion system and its use in vaccine development. Trends Microbiol (2002) 1.46
Can a 'flawless' live vector vaccine strain be engineered? Trends Microbiol (2001) 1.45
A new gene of the f1 operon of Y. pestis involved in the capsule biogenesis. FEBS Lett (1992) 1.44
Caspase-1 activation in macrophages infected with Yersinia pestis KIM requires the type III secretion system effector YopJ. Infect Immun (2008) 1.44
The roles of SsrA-SsrB and OmpR-EnvZ in the regulation of genes encoding the Salmonella typhimurium SPI-2 type III secretion system. Microbiology (2003) 1.43
Nucleotide sequence of the Yersinia pestis gene encoding F1 antigen and the primary structure of the protein. Putative T and B cell epitopes. FEBS Lett (1990) 1.38
Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size. Can J Microbiol (1998) 1.35
Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine (2003) 1.32
The autodisplay story, from discovery to biotechnical and biomedical applications. Microbiol Mol Biol Rev (2007) 1.32
In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun (2000) 1.32
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol (2007) 1.29
Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol (2009) 1.21
New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol (2010) 1.20
Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters. Infect Immun (1998) 1.20
Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 1.17
Stabilization of recombinant avirulent vaccine strains in vivo. Res Microbiol (1991) 1.12
Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients. Clin Vaccine Immunol (2011) 1.10
Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun (2006) 1.08
The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a. FEMS Microbiol Lett (1999) 1.08
Effects of genes exerting growth inhibition and plasmid stability on plasmid maintenance. J Bacteriol (1987) 1.06
A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine (2004) 1.06
A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine (2000) 1.06
Immunity to intracellular Salmonella depends on surface-associated antigens. PLoS Pathog (2012) 1.02
A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun (2009) 1.01
Evaluating metabolic stress and plasmid stability in plasmid DNA production by Escherichia coli. Biotechnol Adv (2012) 1.01
Lymph node colonization dynamics after oral Salmonella Typhimurium infection in mice. PLoS Pathog (2013) 1.00
Altered developmental expression of polymorphic membrane proteins in penicillin-stressed Chlamydia trachomatis. Cell Microbiol (2011) 0.99
Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect Immun (2006) 0.97
Plasmid maintenance in Escherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins. Biotechnol Bioeng (1998) 0.96
Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin Pharmacol Ther (2007) 0.94
Effects of recombinant plasmid size on cellular processes in Escherichia coli. Plasmid (1987) 0.94
Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis (2009) 0.93
Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines. Infect Immun (2010) 0.93
The delicate balance in genetically engineering live vaccines. Vaccine (2013) 0.92
Salmonella enterica as a vaccine carrier. Future Microbiol (2012) 0.92
Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins. Vaccine (2009) 0.91
Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes. Infect Immun (2002) 0.91
Plague: disease, management, and recognition of act of terrorism. Infect Dis Clin North Am (2006) 0.89
Host-vector interactions in Escherichia coli. Adv Biochem Eng Biotechnol (1993) 0.89
Novel methods for expression of foreign antigens in live vector vaccines. Hum Vaccin Immunother (2013) 0.87
Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges. Adv Prev Med (2011) 0.86
Enhanced production of recombinant proteins in Escherichia coli by filamentation suppression. Appl Environ Microbiol (2003) 0.85
The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. Infect Immun (2012) 0.83
Construction of highly attenuated Salmonella enterica serovar Typhimurium live vectors for delivering heterologous antigens by chromosomal integration. Microbiol Res (2008) 0.80
The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague. Adv Prev Med (2011) 0.77
Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comp Immunol Microbiol Infect Dis (2012) 0.76